Gut microbiota regulation may alter lung cancer progression

Three new studies have revealed importance of microbiota the origin, extension and evolution of the lung cancerwhich opens new avenues for early diagnosis there new treatments by regulating its function, according to Dr. Luis Usán, medical director of the biotechnology company Igen Biolab Group.

Usán maintains that “well with probiotics or more easily with postbiotics generated from bacterial consortia could intercede in the microbiota to achieve a better prognosis of the disease“.

According to the expert, there is “a intimate relationship“of the evolution and progression of the disease with metabolic disorders produced by dysbiosis of the gut and lung microbiota.

The first of these three studiespublished in ‘Bioengineered’ and led by Wen Zeng, from Ganzhou Cancer Hospital of Ganzhou University (China), focused on describe differences in gut microbiota healthy patients with the microbiota of patients with lung adenocarcinoma.

Samples of bronchoalveolar lavage fluid were obtained from 46 lung cancer patients non-small cells and 29 with mild lung disease.

In this sense, Usán recalls that “there was evidence significant differences in three genera of bacteria that participate in the regulation of different metabolic pathways cells such as the pentose phosphate pathway, essential for the management of DNA repair, proliferation and metastasis of tumor cells or the glutathione pathway with Properties antioxidantsmaintain or exceed the cell life depending on their levels and their response to chemotherapy“.

Thus, as for the bacterial compositionin the non-small cell lung cancer group, two ‘Phyla’ (‘Firmicutes’, ‘Bacteroidetes’) and three genera (‘Streptococcus’, ‘Prevotella’, ‘Veillonella’) were enriched.

‘Prevotella’ and ‘Veillonella’ were more strongly associated with lung cancer of non-small cells, and ‘Veillonella’ significantly promoted the disease progression ‘live’.

“These different genres can be diagnostic markers potential therapeutic targets,” the researchers explain.

The Second job was published in “Frontiers in Microbiology”. He details that previous studies have shown that the gut microbiota play a big role in the development and progression of metabolic cancers; “However, data on the characteristics of the gut microbiome with different histopathological types of lung cancer remain rare“, determines the study.

Therefore, they collected stool samples of 28 healthy people and 61 patients with lung cancer.

“In this, the characteristics were analyzed, this time from the pulmonary microbiota and its function lung cancer patients non-small cell lung (NSCLC) with the lung microbiota of people with other lung pathologies.

“They found significant differences in the characteristics and abundance of the pulmonary microbiota, and in particular bacteria of the genus ‘Prevotella’ and ‘Veillonella'”, says the expert from the Igen Biolab group.

“Again, they observed alterations in metabolic pathways related to the synthesis of metabolites, ribosomes and pyrimidine like responsible for disease progression“, he repeats.

Finally, the third surveyof “Frontiers in Oncology”, was also carried out with stool samples of 100 attendees. “In this case, we analyzed the gut dysbiosis relationship with the histopathological characteristics of the different times of progression of lung cancer“, introduce.

“A decrease in bacteria was observed with anti-inflammatory properties compared to healthy subjects and an increase of pro-inflammatory bacteria oh tumor promoters in patients with oncological diseasethese modifications being more important in people affected with a more important histopathological progression, which is accompanied by modifications of the cellular metabolic pathways”, recalls the expert.

These studies, he adds, “reveal the importance of the microbiota in lung cancer“. In any case, he adds, “it will be necessary Clinical studies who demonstrate their utility in these patients.

Leave a Comment